drugset
drugset / Trial / NCT02448719

Single-Dose Phase 1 Study of TAK-792

NCT02448719 ↗

Phase 1 Completed 72 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to characterize the safety and tolerability profile of TAK-792 when administered as a single oral dose in healthy Japanese and Caucasian male participants.

Timeline

Start
2015-05-27
Primary completion
2016-01-28
Completion
2016-01-28

Drugs

EvaluationDrugModalityDoseRoute
Subject TAK-792 Unknown 30 mg Oral
Subject TAK-792 Unknown 100 mg Oral
Subject TAK-792 Unknown 250 mg Oral
Subject TAK-792 Unknown 500 mg Oral
Subject TAK-792 Unknown 750 mg Oral
Subject TAK-792 Unknown 1250 mg Oral

Indications

No indication recorded.